NASDAQ:TOCA Tocagen (TOCA) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free TOCA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.71▼$0.7450-Day Range$1.26▼$41.0352-Week Range$0.42▼$6.77Volume5,733 shsAverage Volume1.47 million shsMarket Capitalization$17.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Tocagen alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Tocagen Stock (NASDAQ:TOCA)Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. TOCA Stock News HeadlinesDecember 11, 2023 | markets.businessinsider.comRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingNovember 2, 2023 | finance.yahoo.comProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 28, 2023 | marketwatch.comAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029February 27, 2023 | marketwatch.comCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029September 28, 2022 | marketwatch.comCompanion Diagnostics Market to show impressive growth of 11.04% CAGR during the period 2022-2027 | 102 Report PagesApril 16, 2022 | streetinsider.comForm DEF 14A Mirati Therapeutics, For: May 12 - StreetInsider.comMarch 31, 2022 | marketscreener.comFORTE BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.comApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 30, 2022 | newsweek.comWhat Is Glioblastoma? Aggressive Cancer Linked to Death of Tom Parker - NewsweekDecember 22, 2021 | seekingalpha.comWeek In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board - Seeking AlphaDecember 16, 2021 | finance.yahoo.comDenovo Biopharma LLC Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB107 for a Gene Therapy-Based Medicine - Yahoo FinanceSeptember 20, 2021 | washingtonpost.comChasing Cancer with Meg Kinnard - The Washington PostAugust 16, 2021 | marketscreener.comFORTE BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.comSee More Headlines Receive TOCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tocagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2020Today4/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TOCA CUSIPN/A CIK1419041 Webwww.tocagen.com Phone858-412-8400FaxN/AEmployees77Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,520,000.00 Net Margins-176,433.34% Pretax MarginN/A Return on Equity-327.74% Return on Assets-111.87% Debt Debt-to-Equity Ratio1.88 Current Ratio1.15 Quick Ratio1.15 Sales & Book Value Annual Sales$40,000.00 Price / Sales428.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.59Miscellaneous Outstanding Shares23,919,000Free FloatN/AMarket Cap$17.13 million OptionableNot Optionable Beta0.01 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Martin J. Duvall (Age 57)CEO & Director Mr. Thomas E. Darcy (Age 68)Co-Founder & Director Dr. Douglas J. Jolly (Age 71)Co-Founder and Exec. VP of Research & Pharmaceutical Devel. Mr. Mark G. Foletta C.P.A. (Age 58)CPA, Exec. VP & CFO Dr. Harry E. Gruber (Age 66)Founder, Adviser & Director Key CompetitorsVBI VaccinesNASDAQ:VBIVMinerva NeurosciencesNASDAQ:NERVBenitec BiopharmaNASDAQ:BNTCOrgenesisNASDAQ:ORGSFSD PharmaNASDAQ:HUGEView All Competitors TOCA Stock Analysis - Frequently Asked Questions How were Tocagen's earnings last quarter? Tocagen Inc (NASDAQ:TOCA) released its earnings results on Thursday, April, 23rd. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. Tocagen had a negative trailing twelve-month return on equity of 327.74% and a negative net margin of 176,433.34%. What other stocks do shareholders of Tocagen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), T2 Biosystems (TTOO), Amarin (AMRN), Novavax (NVAX), OPKO Health (OPK) and Amicus Therapeutics (FOLD). When did Tocagen IPO? Tocagen (TOCA) raised $80 million in an initial public offering (IPO) on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO. This page (NASDAQ:TOCA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
